Health leaders at the International AIDS Society (IAS) 2025 conference in Kigali have warned that shrinking funding and ...

As science soars with game-changing HIV tools, a funding crisis threatens to ground progress "We come together at a pivotal time for the HIV response, one defined by both incredible scientific ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

New WHO guidelines endorse long-acting injectable lenacapavir for HIV prevention, Medicines Patent Pool expands licence for long-acting injectable cabotegravir for treatment, and Merck’s once-monthly ...

A breakthrough to reduce risk of HIV in adolescents and adults weighing at least 35 kg. WHO releases the new guidelines ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...

The World Health Organisation (WHO) has called for the immediate global rollout of a breakthrough HIV drug, lenacapavir (LEN) ...

The World Health Organization (WHO) has issued new guidelines recommending the twice-yearly use of injectable lenacapavir ...

The World Health Organization now recommends lenacapavir, a twice-yearly injectable HIV prevention drug, especially for high-risk groups. This endorsement arrives amidst funding concerns, with Gilead ...

Increasing the use of Apretude among Black women requires not only expanding awareness of the long-acting PrEP regimen in ...

IAS 2025, the 13th IAS Conference on HIV Science, opened today with a call to accelerate access to long-acting HIV prevention and treatment innovations amid growing global funding challenges. Four ...